ARTICLE
14 February 2024

Licensing To Engage In Pharmaceutical Activity

P
PLMJ

Contributor

PLMJ is a law firm based in Portugal that combines a full service with bespoke legal craftsmanship. For more than 50 years, the firm has taken an innovative and creative approach to produced tailor-made solutions to effectively defend the interests of its clients. The firm supports its clients in all areas of the law, often with multidisciplinary teams, and always acting as a business partner in the most strategic decision-making processes.
The Regulations on Licensing to Engage in Pharmaceutical Activity ("RLEAF") applies to all natural and legal persons in the private sector who carry out pharmaceutical activities in Angola.
Angola Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

The Regulations on Licensing to Engage in Pharmaceutical Activity ("RLEAF") applies to all natural and legal persons in the private sector who carry out pharmaceutical activities in Angola.

Presidential Decree 41/24 of 29 January - Regulations on Licensing to Engage in Pharmaceutical Activity ("RLEAF") was recently published to establish the rules and procedures for licensing to engage in pharmaceutical activity. It also repeals Articles 8, 9, 11, 13, 47 and 49 of the Regulations on Engaging in Pharmaceutical Activity, approved by Presidential Decree 191/10, approved by Presidential Decree 191/10, approved by Presidential Decree 191/10 of 1 September, and Presidential Decree 202/21 of 26 August.

The RLEAF applies to all natural and legal persons in the private sector who carry out pharmaceutical activities in Angola, through the following establishments: (i) pharmacies; (i) retailers of herbal medicine; (iii) retailers of cosmetics; (iv) retailers of health products; (v) distributors of medicines or health technologies, and (vi) importers of medicines or health technologies.

These are the main changes:

  • Simplification of the documentation required for the purposes of the licensing process, with some previously required documents no longer being required;
  • Establishment of a maximum legal period of 30 (thirty) days, from the date of the interested party's application and once the establishment has been completed, for an inspection of the establishment to be carried out;
  • Establishment of a maximum legal period of 3 (three) working days for the Regulatory Agency for Medicines and Health Technologies ("ARMED") to grant the interested party the authorisation to open and operate the pharmaceutical establishment, once the inspection has been completed and a favourable opinion has been issued by the integrated Technical Commission;
  • Establishment of the exclusivity and non-transferability of the authorisation, except in cases of transfer and assignment of commercial operation of the establishment, which must be communicated to ARMED for licensing purposes.
  • Reinforcement of the rules on administrative offence for offences committed under the RLEAF.

In general, these changes are aimed at speeding up the procedures for granting authorisations to carry out pharmaceutical activities, in line with the guidelines established under the SIMPLIFICA 2.0 project, approved by Presidential Decree 182/22 of 22 July.

The law entered into force on the date of its publication.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More